Evidence map›Paper›PMID 40437755›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Disease-modifying, multidimensional efficacy of putaminal Ca

Kathy Steece-Collier, Margaret E Caulfield, Molly J Vander Werp, Scott J Muller, Jennifer A Stancati, Yaping Chu, Ivette M Sandoval, Timothy J Collier, Jeffrey H Kordower, Fredric P Manfredsson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Genetic Variants inInternational journal of molecular sciences · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kathy Steece-CollierDepartment of Translational Neuroscience, College of Human Medicine, Michigan State University, 400 Monroe Avenue NW, Grand Rapids, MI 49503, USA. Electronic address: collie68@msu.edu.
Margaret E CaulfieldDepartment of Translational Neuroscience, College of Human Medicine, Michigan State University, 400 Monroe Avenue NW, Grand Rapids, MI 49503, USA.
Molly J Vander WerpDepartment of Translational Neuroscience, College of Human Medicine, Michigan State University, 400 Monroe Avenue NW, Grand Rapids, MI 49503, USA.
Scott J MullerASU-Banner Neurodegenerative Disease Research Center (NDRC), School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA.
Jennifer A StancatiDepartment of Translational Neuroscience, College of Human Medicine, Michigan State University, 400 Monroe Avenue NW, Grand Rapids, MI 49503, USA.
Yaping ChuASU-Banner Neurodegenerative Disease Research Center (NDRC), School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA.
Ivette M SandovalParkinson's Disease Research Unit, Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ 85013, USA.
Timothy J CollierDepartment of Translational Neuroscience, College of Human Medicine, Michigan State University, 400 Monroe Avenue NW, Grand Rapids, MI 49503, USA.
Jeffrey H KordowerASU-Banner Neurodegenerative Disease Research Center (NDRC), School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA.
Fredric P ManfredssonParkinson's Disease Research Unit, Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ 85013, USA.

Funding

Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PDR01NS110398 · NINDS · MICHIGAN STATE UNIVERSITY · PI Jeffrey H Kordower, Fredric Manfredsson · 2018 to 2026
$5.3M
NINDS NIH HHS R01 NS110398
6 · The paper itself

Abstract

There remain several unmet clinical needs in Parkinson's disease (PD) including waning and incomplete efficacy of symptomatic therapies, development of medication side effects (i.e., levodopa-induced dyskinesias [LID]) and unfettered disease progression. Ca

Indexed as

Calcium Channels, L-TypeGenetic TherapyParkinson DiseaseParkinsonian DisordersPutamenRNA, Small InterferingAnimalsDependovirusDisease Models, AnimalFemaleGenetic VectorsHumansMagnetic Resonance ImagingMaleRNA InterferenceCalcium Channels, L-TypeRNA, Small InterferingCa(V)1.3 channelsgene therapylevodopa-induced dyskinesiamotor dysfunctionnonhuman primateParkinson’s disease

Identifiers

PMID40437755
PMCPMC12382360

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.